DobbieJ.W.Morphology of the peritoneum in CAPD.Blood Purif1989; 7: 74–85.
2.
HeimburgerO., WaniewskiJ., WeryñskiA.Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity.Kidney Int1990; 38: 495–506.
3.
LiberekT., TopleyN., JörresA.Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration.J Am Soc Nephrol1993; 3: 1508–15.
4.
JorresA., GahlG.M., FreiU.In vitro studies on the effect of dialysis solutions on peritoneal leukocytes.Perit Dial Int1995; 15: S41–6.
5.
DawnayA.Advanced glycation end products in peritoneal dialysis.Perit Dial Int1996; 16: S50–3.
6.
YamadaK., MiyaharaY., HamaguchiK.Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure.Clin Nephrol1994; 42: 354–61.
7.
BeelenR.H.J., van der MeulenJ., VerbrughH.A.CAPD, a permanent state of peritonitis: a study on peroxidase activity. In: MaherJ.F., WinchesterJ.F., eds. Frontiers in Peritoneal Dialysis.New York: Field, Rich, 1986; 524–30.
8.
BrulezH.F.H., VerbrughH.A.First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis.Perit Dial Int1995; 15: S24–34.
9.
DobbieJ.W.Durability of the peritoneal membrane.Perit Dial Int1995; 15: S87–92.
10.
BreborowiczA., MartisL., OreopoulosD.G.Changes in biocompatibility of dialysis fluid during its dwell in the peritoneal cavity.Perit Dial Int1995; 15: 152–170.
11.
BosH.J., MeyerF., VeldJ.C.Peritoneal dialysis fluid induces a change of mononuclear phagocyte properties.Kidney Int1989; 36: 20–6.
12.
DobbieJ.W.Serositis: comparative analysis of histological findings and pathogenetic mechanisms in nonbacterial serosal inflammation.Perit Dial Int1993; 13: 256–69.
13.
ChanM.K., ChowL., LamS.S.Peritoneal eosinophilia in patients on continuous ambulatory peritoneal dialysis: a prospective study.Am J Kidney Dis1988; 11: 180–3.
14.
DaviesS.J., SuassunaJ., OggC.S.Activation of immunocompetent cells in the peritoneum of patients treated with CAPD.Kidney Int1989; 36: 661–8.
15.
BetjesM.G.H., TukC.W., StruijkD.G.Immuno-effector characteristics of peritoneal cells during CAPD treatment: A longitudinal study.Kidney Int1993; 43: 641–8.
16.
LibettaC., De NicolaL., RampinoT.Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation.Kidney Int1996; 49: 506–11.
17.
McGregorS.J., TopleyN., JörresA.Longitudinal evaluation of peritoneal macrophage function and activation during CAPD: Maturity, cytokine synthesis and arachidonic acid metabolism.Kidney Int1996; 49: 525–33.
18.
BosH.J., StruijkD.G., TukC.W.Peritoneal dialysis induces a local sterile inflammatory state and the mesothelial cells in the effluent are related to the bacterial peritonitis incidence.Nephron1991; 59: 508–9.
19.
GoldmanM., VandenabeeleP., MoulartJ.Intraperitoneal secretion of interleukin-6 during continuous ambulatory peritoneal dialysis.Nephron1990; 56: 277–80.
20.
BetjesM.G.H., VisserC.E., ZemelD.Intraperitoneal interleukin-8 and neutrophil influx in the initial phase of a CAPD peritonitis.Perit Dial Int1996; 16: 385–92.
21.
SnitkoffG., BailieG.R., EiseleG.Interleukin, endotoxin and tumor necrosis factor in CAPD dialysate.Perit Dial Int1995; 15: 279–80.
22.
MarianoF., TettaC., MontrucchioG.Role of alphal-proteinase inhibitor in restraining peritoneal inflammation in CAPD patients.Kidney Int1992; 42: 735–42.
23.
ZemelD., ImholzA.L.T., de WaartD.R.Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD.Kidney Int1994; 46: 1422–30.
24.
TaylorJ.E., ScottN., BridgesA.Lipid peroxidation and antioxidants in continuous ambulatory dialysis patients.Perit Dial Int1992; 12: 252–6.
25.
BreborowiczA., KaronJ., KorybalskaK.Functional properties of mesothelial cells after prolonged exposure to dialysate effluent. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1995; 11: 15–8.
26.
SelgasR., Lopez-RivasA., MirandaB.Characterisation of the mitogenic-induced capacity of peritoneal effluent on human and mice fibroblasts and culture.Nephrol Dial Transpl1991; 6: 44–50.
27.
BreborowiczA., KorybalskaK., GrzybowskiA.Synthesis of hyaluronic acid by human peritoneal mesothelial cells: effect of cytokines and dialysate.Perit Dial Int1996; 16: 374–8.
28.
FreimanJ.P., GrahamD.J., ReedT.G.Chemical peritonitis following the intraperitoneal administration of vancomycin.Perit Dial Int1992; 12: 57–60.
29.
JunorB.J.R., BriggsJ.D., ForwellM.A.Sclerosing peritonitis — the contribution of chlorhexidine in alcohol.Perit Dial Bull1985; 5: 101–4.
30.
FracassoA., ColiU., LandiniS.Peritoneal sclerosis. Role of plasticizers.Trans Am SocArtif Intern Organs1987; XXXIII: 676–82.
31.
MettangT., ThomasS., KieferT.The fate of leached di(2-ethylhexyl)phtalate in patients undergoing CAPD treatment.Perit Dial Int1996; 16: 58–62.
32.
ProwantB., NolphK., RyanL.Peritonitis in continuous ambulatory peritoneal dialysis: analysis of an 8-year experience.Nephron1986; 43: 105–9.
33.
ShaldonS., KochK.M., QuellhorstE.Pathogenesis of sclerosing peritonitis in CAPD.Trans Am SocArtif Intern Organs1984; 30: 193–4.
34.
VlassaraH., BrownleeM., ManogueK.R.Cachectin/TNF and Il-1 induced by glucose-modified proteins: Role in normal tissue remodelling.Science1998; 240: 1546–8.
35.
VlassaraH.Advanced Nonenzymatic Tissue Glycosylation: cell-mediated interactions implicated in the complications associated with diabetes and aging.Blood Purif1990; 8: 223–32.
36.
HaussingerD., LangF., GerokW.Regulation of cell function by the cellular hydration state.Am J Physiol1994; 267: E343–55.
37.
BreborowiczA., RodelaH., KaronJ.In vitro simulation of the effect of peritoneal dialysis solution on mesothelial cells.Am J Kidney Dis. In press.
38.
van HinsberghV.W.M., KooistraT., SchefferM.A.Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells.Blood1990; 75: 1490–7.
39.
GriesE., PaarD., GrabenN.Intraperitoneal fibrin-formation and its inhibition in CAPD.Clin Nephrol1986; 26: 209–12.
40.
SitterT., SpannaglM., SchifflH.Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells.Nephrol Dial Transpl1995; 10: 677–83.
41.
SlaterN.D., CopeG.H., RafteryA.T.Peritoneal plasminogen activator activity after chronic exposure to dialysis fluid.Perit Dial Int1992; 12: 262–3.
42.
Ho-Dac-PannekeetM., KredietR.Inflammatory changes in vivo during CAPD: What can the effluent tell us?Kidney Int1996; 50: S12–6.
43.
DobbieJ.W.Pathogenesis of Peritoneal Fibrosing Syndromes (Sclerosing Peritonitis) in Peritoneal Dialysis.Perit Dial Int1992; 12: 14–27.
44.
FriedmanE.A.Will pimagidine improve survival of diabetics on dialysis?Nephrol Dial Transpl1996; 11: 1524–7.
45.
KeaneW.F., VasS.I.Peritonitis. In: GokalR., NolphK.G., eds. The textbook of peritoneal dialysis.Dordrecht/ Boston/London: Kluwer Academic Publishers, 1994; 473–501.
46.
BreborowiczA., WieczorowskaK., MartisL.Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats.Nephron1994; 67: 346–50.
47.
BazzatoG., FracassoA., ReG.Use of glycosam-inoglycans to increase efficiency of long-term continuous peritoneal dialysis.Lancet1995; 346: 740–1.
48.
WieczorowskaK., BreborowiczA., MartisL.Protective effect of hyaluronic acid against peritoneal injury.Perit Dial Int1995; 15: 81–3.
49.
YungS., ColesG.A., WilliamsJ.D.The source and possible significance of hyaluronan in the peritoneal cavity.Kidney Int1994; 46: 527–33.
50.
LipkinG.W., ForbesM.A., CooperEHHyaluronic acid metabolism and its clinical significance in patients treated by continuous ambulatory peritoneal dialysis.Nephrol Dial Transpl1993; 8: 357–60.
51.
ForresterJ.V., BalazsE.A.Inhibition of phagocytosis by high molecular weight hyaluronate.Immunology1980; 40: 435–46.
52.
SuzukiY., YamaguchiT.Effects of hyaluronic acid on macrophage phagocytosis and active oxygen release.Agents Action1993; 38: 32–7.
53.
AkatsukaM., YamamotoY., TobettoK.Suppressive effects of hyaluronic acid on elastase release from rat peritoneal leukocytes.J Pharm Pharmacol1993; 45: 110–4.
54.
WeigelP.H., FullerG.M., LeBoeufR.D.Amodel for the role of hyaluronic acid and fibrin in early events during the inflammatory response and wound healing.J TheorBiol1986; 119: 219–26.
55.
NagyJ.A.Peritoneal membrane morphology and function.Kidney Int1996; 50: S2–11.
